Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988405 | 0.92 | CYP4F2 (0.36) | CYP4F2CYP4A11ACLYPPARALTB4R | |
| SCHEMBL2989709 | 0.85 | ACLY (0.47) | CYP4F2CYP4A11ACLYPPARALTB4R | |
| SCHEMBL6275321 | 0.82 | ACLY (0.34) | CYP4F2CYP4A11ACLYPPARAACACB | |
| SCHEMBL2983798 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11PPARACES2 | |
| SCHEMBL2988805 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11PPARACES2 | |
| SCHEMBL22688274 | 0.77 | ACACB (0.35) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL1114607 | 0.75 | ACLY (0.38) | CYP4F2CYP4A11ACLYACACBACACA | |
| Gemcabene SCHEMBL761631 | 0.74 | ACLY (0.55) | CYP4F2CYP4A11ACLYPPARALTB4R | |
| SCHEMBL13210378 | 0.73 | MEN1 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL10518207 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777071-B2 | Production of carnitine conjugate intermediates | SSV THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | SSV THERAPEUTICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008018877-A1 | CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF | SSV THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | CPT1B, CRAT, CPT2 | CYP4F2 102/4885CYP4A11 244/4885ACLY 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.